Antitumor effect of allogenic fibroblasts engineered to express Fas ligand (FasL)

Gene Therapy

Volumn 5, Issue 12, 1998, Pages 1622-1630

  Drozdzik, M ^a   Qian, C ^a   Lasarte, J J ^a   Bilbao, R ^a   Prieto, J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Animal; Fas ligand; Gene transfer; Tumor

Indexed keywords

CD8 ANTIGEN; FAS LIGAND;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARCINOGENICITY; CELL INFILTRATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; FIBROBLAST; GENETIC ENGINEERING; GRAFT REJECTION; HISTOLOGY; HUMAN; IMMUNITY; LIVER CELL; MONONUCLEAR CELL; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL;

ANIMALIA;

EID: 0032429135     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300763     Document Type: Article

References (13)

1. Takahashi T et al. Human Fas ligand: gene structure chromosomal location and species specificity. Int Immunol 1994; 6: 1567-1574.
2. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1178.
3. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol 1994; 57: 129-144.
4. Kagi D et al. Fas and perforin pathway as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-539.
5. Lowin B, Hahne M, Matthman C, Tschopp J. Cytotoxic T cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-652.
6. Kondo T et al. Essential roles of the Fas ligand in the development of hepatitis. Nature Med 1997; 3: 409-413.
7. Rieux-Lucat F et al. Mutations in Fas associated with human lymphoproliferation syndrome and autoimmunity. Science 1995; 268: 1347-1349.
8. Fischer GH et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995; 81: 935-946.
9. Matsuzawa A et al. A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadanopathy in the mouse. J Exp Med 1990; 171: 519-539.
10. Takahashi T et al. Generalized lymphoproliferative disease in mice caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-976.
11. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today 1995; 16: 569-574.
12. Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today 1997; 18: 240-244.
13. Griffith TS et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-1192.